Accelerated Bone Degradation in Thyroid Carcinoma Patients during Thyroxine Treatment, Measured by Determination of the Carboxyterminal Telopeptide Region of Type I Collagen in Serum
- 1 January 1994
- journal article
- research article
- Published by Walter de Gruyter GmbH in cclm
- Vol. 32 (11) , 827-832
- https://doi.org/10.1515/cclm.1994.32.11.827
Abstract
We studied the effects of long-term suppressive thyroxine treatment on serum markers of bone collagen synthesis and degradation in thyroid carcinoma patients, and the relationship of these effects to the serum concentrations of thyrotropin, free thyroxine and free triiodothyronine were investigated. Thirty-seven thyroid carcinoma patients receiving a stable thyroxine dose, and thirty-five controls participated in a cross-sectional study. Bone collagen synthesis and degradation were measured by using specific radioimmunoassays to determine the serum concentrations of carboxyterminal propeptide of type I procollagen, and carboxyterminal telopeptide region of type I collagen, respectively. Serum thyrotropin, free T4 and free T3 were measured by time-resolved fluoroimmunoassays (Delfia). Serum carboxyterminal telopeptide region of type I collagen concentrations of thyroid carcinoma patients were significantly higher than those of the controls (p = 0.0012). Serum carboxyterminal propeptide of type I procollagen concentrations did not differ significantly between the patients and controls (p = 0.85). Significant associations between age or physical activity, and carboxyterminal propeptide of type I procollagen or carboxyterminal telopeptide region of type I collagen were found in the controls, but not in the patients. Thyrotropin, free T4 or free T3 were not significantly associated with carboxyterminal propeptide of type I procollagen or carboxyterminal telopeptide region of type I collagen in either the control or patient group. From these results it is concluded that long-term suppressive thyroxine treatment seems to accelerate bone degradation, but not bone formation, and therefore carries a risk for osteoporosis.(ABSTRACT TRUNCATED AT 250 WORDS)Keywords
This publication has 12 references indexed in Scilit:
- Time-resolved immunofluorometric assay for thyrotropin improved for enhanced functional sensitivity and clinical discriminationScandinavian Journal of Clinical and Laboratory Investigation, 1994
- Bone mineral density in patients with hyperthyroidism measured by dual energy X‐ray absorptiometryClinical Endocrinology, 1993
- Management of a Solitary Thyroid NoduleNew England Journal of Medicine, 1993
- Long-term thyroxine treatment and bone mineral densityThe Lancet, 1992
- Skeletal integrity in premenopausal and postmenopausal women receiving long-term L-thyroxine therapyThe American Journal of Medicine, 1991
- Measurement of Bone Collagen Degradation in Hyperthyroidism and During Thyroxine Replacement Therapy Using Pyridinium Cross-Links as Specific Urinary Markers*Journal of Clinical Endocrinology & Metabolism, 1991
- A Therapeutic Dilemma: Suppressive Doses of Thyroxine Significantly Reduce Bone Mineral Measurements in Both Premenopausal and Postmenopausal Women with Thyroid CarcinomaJournal of Clinical Endocrinology & Metabolism, 1991
- Bone mineral density in postmenopausal women treated with L-thyroxineThe American Journal of Medicine, 1991
- Long-term L-thyroxine therapy is associated with decreased hip bone density in premenopausal womenJAMA, 1988
- Subclinical Hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with L-ThyroxineThe American Journal of Medicine, 1987